(SVRA) Savara - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.142m USD | Total Return: 103.6% in 12m

Rare Diseases, Respiratory, Biopharmaceutical, Treatments
Total Rating 51
Safety 68
Buy Signal 0.02
Biotechnology
Industry Rotation: +3.6
Market Cap: 1.14B
Avg Turnover: 8.34M USD
ATR: 5.66%
Peers RS (IBD): 64.8
Risk 5d forecast
Volatility61.3%
Rel. Tail Risk-6.07%
Reward TTM
Sharpe Ratio1.19
Alpha77.84
Character TTM
Beta0.879
Beta Downside1.563
Drawdowns 3y
Max DD65.30%
CAGR/Max DD0.74
EPS (Earnings per Share) EPS (Earnings per Share) of SVRA over the last years for every Quarter: "2021-03": -0.13, "2021-06": -0.07, "2021-09": -0.07, "2021-12": -0.07, "2022-03": -0.05, "2022-06": -0.06, "2022-09": -0.07, "2022-12": -0.07, "2023-03": -0.07, "2023-06": -0.07, "2023-09": -0.1, "2023-12": -0.09, "2024-03": -0.11, "2024-06": -0.12, "2024-09": -0.1145, "2024-12": -0.13, "2025-03": -0.12, "2025-06": -0.14, "2025-09": -0.14, "2025-12": -0.13, "2026-03": 0,
EPS CAGR: 14.53%
EPS Trend: -34.6%
Last SUE: 4.00
Qual. Beats: 1
Revenue Revenue of SVRA over the last years for every Quarter: 2021-03: 0.001, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 0, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 0.272, 2025-03: 0, 2025-06: 0, 2025-09: 0, 2025-12: 0, 2026-03: null,
Rev. CAGR: 0.00%
Rev. Trend: 19.6%
Last SUE: 0.00
Qual. Beats: 0
Warnings

Altman Z'' -15.00 < 1.0 - financial distress zone

choppy

Tailwinds

No distinct edge detected

Description: SVRA Savara

Savara Inc. (SVRA) is a clinical-stage biopharmaceutical company specializing in treatments for rare respiratory diseases. The companys primary focus is molgramostim, an inhaled therapy currently in Phase 3 trials for autoimmune pulmonary alveolar proteinosis. Biopharmaceutical companies typically incur significant research and development costs as they advance drug candidates through clinical phases.

Founded in 2007 and headquartered in Langhorne, Pennsylvania, Savara operates within the Biotechnology sub-industry. The business model for such companies often relies on successful drug development and commercialization, with potential for high returns balanced by substantial regulatory and clinical risks. For more in-depth analysis of Savaras pipeline and market position, consider exploring ValueRay.

Headlines to Watch Out For
  • Molgramostim Phase 3 trial results impact stock
  • Regulatory approval for molgramostim crucial for revenue
  • Funding availability for clinical trials affects operations
  • Competition in rare respiratory disease market poses risk
Piotroski VR‑10 (Strict) 0.0
Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM)
FCF/TA: -0.40 > 0.02 and ΔFCF/TA 1.99 > 1.0
NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.40 > 3% & CFO -101.0m > Net Income -118.8m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 11.85 > 1.5 & < 3
Outstanding Shares: last quarter (222.4m) vs 12m ago 12.21% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.0% > 50% (prev 0.13%; Δ -0.13% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM)
Altman Z'' -15.00
A: 0.87 (Total Current Assets 241.6m - Total Current Liabilities 20.4m) / Total Assets 253.4m
B: -2.40 (Retained Earnings -608.1m / Total Assets 253.4m)
C: -0.52 (EBIT TTM -122.1m / Avg Total Assets 233.2m)
D: -12.09 (Book Value of Equity -608.0m / Total Liabilities 50.3m)
Altman-Z'' Score: -18.30 = D
Beneish M
DSRI: none (Receivables 1.25m/1.04m, Revenue 0.0/272k)
GMI: 1.00 (fallback, negative margins)
AQI: 0.93 (AQ_t 0.05 / AQ_t-1 0.05)
SGI: none (Revenue 0.0 / 272k)
TATA: -0.07 (NI -118.8m - CFO -101.0m) / TA 253.4m)
Beneish M-Score: cannot calculate (missing components)
What is the price of SVRA shares? As of April 07, 2026, the stock is trading at USD 5.56 with a total of 811,600 shares traded.
Over the past week, the price has changed by +10.89%, over one month by +6.26%, over three months by +1.08% and over the past year by +103.64%.
Is SVRA a buy, sell or hold? Savara has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy SVRA.
  • StrongBuy: 4
  • Buy: 2
  • Hold: 2
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the SVRA price?
Analysts Target Price 10.8 94.4%
Savara (SVRA) - Fundamental Data Overview as of 03 April 2026
P/E Forward = 0.4076
P/S = 145272.6216
P/B = 5.6168
Revenue TTM = 0.0 USD
EBIT TTM = -122.1m USD
EBITDA TTM = -121.9m USD
Long Term Debt = 29.9m USD (from longTermDebt, last quarter)
Short Term Debt = 7.00k USD (from shortTermDebt, last quarter)
Debt = 29.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -3.27m USD (from netDebt column, last quarter)
Enterprise Value = 936.2m USD (1.14b + Debt 29.9m - CCE 235.7m)
 Interest Coverage Ratio = unknown (Ebit TTM -122.1m / Interest Expense TTM 0.0)
 EV/FCF = -9.26x (Enterprise Value 936.2m / FCF TTM -101.1m)
FCF Yield = -10.79% (FCF TTM -101.1m / Enterprise Value 936.2m)
 FCF Margin = unknown (Revenue TTM is 0 or missing)
 Net Margin = unknown
 Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 1.33m) / Revenue TTM)
 Tobins Q-Ratio = 3.69 (Enterprise Value 936.2m / Total Assets 253.4m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 29.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -96.4m (EBIT -122.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 11.85 (Total Current Assets 241.6m / Total Current Liabilities 20.4m)
Debt / Equity = 0.15 (Debt 29.9m / totalStockholderEquity, last quarter 203.1m)
 Debt / EBITDA = 0.03 (negative EBITDA) (Net Debt -3.27m / EBITDA -121.9m)
 Debt / FCF = 0.03 (negative FCF - burning cash) (Net Debt -3.27m / FCF TTM -101.1m)
 Total Stockholder Equity = 141.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -50.97% (Net Income -118.8m / Total Assets 253.4m)
RoE = -84.01% (Net Income TTM -118.8m / Total Stockholder Equity 141.5m)
RoCE = -71.24% (EBIT -122.1m / Capital Employed (Equity 141.5m + L.T.Debt 29.9m))
 RoIC = -56.34% (negative operating profit) (NOPAT -96.4m / Invested Capital 171.2m)
 WACC = 8.85% (E(1.14b)/V(1.17b) * Re(9.08%) + D(29.9m)/V(1.17b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.08% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 11.20%
 [DCF] Fair Price = unknown (Cash Flow -101.1m)
 EPS Correlation: -34.61 | EPS CAGR: 14.53% | SUE: 4.0 | # QB: 1
Revenue Correlation: 19.60 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.14 | Chg7d=+0.000 | Chg30d=-0.019 | Revisions Net=-1 | Analysts=6
EPS current Year (2026-12-31): EPS=-0.47 | Chg7d=+0.000 | Chg30d=-0.067 | Revisions Net=-5 | Growth EPS=+11.9% | Growth Revenue=+0.0%
EPS next Year (2027-12-31): EPS=-0.32 | Chg7d=+0.000 | Chg30d=-0.118 | Revisions Net=-3 | Growth EPS=+31.4% | Growth Revenue=+350.6%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle